TD Waterhouse Canada Inc. Has $7.58 Million Holdings in Boston Scientific Corporation $BSX

Posted by Brian Himes on Sep 6th, 2026

Boston Scientific logo TD Waterhouse Canada Inc. cut its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 41.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 176,096 shares of the medical equipment provider’s stock after selling 122,142 shares during the period. TD Waterhouse Canada Inc.’s holdings in Boston Scientific were worth $7,584,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific during the second quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter worth approximately $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in Boston Scientific during the 1st quarter worth approximately $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific’s ICVT Business Gains Momentum
Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Trading Up 1.9%

Boston Scientific stock opened at $47.85 on Friday. The company’s fifty day simple moving average is $46.90 and its 200-day simple moving average is $55.74. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The stock has a market cap of $69.35 billion, a P/E ratio of 19.37, a P/E/G ratio of 1.10 and a beta of 0.57.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward Ludwig purchased 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. UBS Group reduced their target price on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Royal Bank Of Canada lowered their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Oppenheimer reduced their price objective on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Weiss Ratings lowered Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Finally, Evercore set a $65.00 target price on Boston Scientific in a research note on Monday, July 6th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Check Out Our Latest Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.